36187-57-2

Basic information

• Product Name: Ethanone, 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]-
• CAS NO: 36187-57-2
• Molecular Formula: C15H13FOS
• Molecular Weight: 260.332
• Mol File: 36187-57-2.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]-(36187-57-2)
• EPA Substance Registry System: Ethanone, 1-(4-fluorophenyl)-2-[4-(methylthio)phenyl]-(36187-57-2)

Safety Data

• Hazardous Substances Data: 36187-57-2(Hazardous Substances Data)

Upstream product

• 177755-36-1 2-(4-fluorophenyl)-3-(4-methylthiophenyl)propenoic acid 
• 75-65-0 tert-butyl alcohol 
• 7647-01-0 hydrogenchloride 
• 100-68-5 methyl-phenyl-thioether 
• 7677-24-9 trimethylsilyl cyanide 
• 874-87-3 1-(chloromethyl)-4-methylthiobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 405-51-6 4-fluorophenyl acetate 
• 462-06-6 fluorobenzene 
• 63327-11-7 4-methylthiophenyl acetic chloride 

Downstream Products

• 71006-38-7 1-(4-fluorophenyl)-2-(4-methylthiophenyl)-2-bromoethanone 
• 221057-71-2 3-(4-Fluorobenzoyl)-3-(4-methylthiophenyl)propionic acid, ethyl ester 
• 132470-23-6 cis,trans-3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)phenyl)propenal 
• 177561-18-1 1-(4-methylthiophenyl)-2-bromo-2-(4-fluorophenyl)-1-ethanone 
• 132470-25-8 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone 
• 165252-26-6 3-amino-2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]-4,4,4,-trifluoro-2-butenone 
• 140403-87-8 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]thiophene-2-sulfonic acid 
• 140402-47-7 methyl 5-(4-fluorophenyl)-4-[4-(methylsulfonyl)phenyl]thiophene-2-acetate 

Relevant articles and documents

PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS

The present invention describes pyridazinone compounds which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important "housekeeping" enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors

A series of 2-phenylpyran-4-ones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. Compounds having a p-methylsulfone group at the 2-phenyl ring showed the best COX-2 inhibitory activity. The introduction of a substituted phenoxy ring at position 3 enhanced both the in vitro and in vivo activity within the series. A selected group of 3-phenoxypyran-4-ones exhibited excellent activity in an experimental model of pyresis. The in vivo antiinflammatory activity of these compounds was confirmed with the evaluation of their antiarthritic and analgesic effectiveness. Moreover, their pharmacokinetic profile in rats is compatible with a once a day administration by oral route in humans. Within this novel series, compounds 21, 31, 34, and 35 have been selected for further preclinical and clinical evaluation.

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazione compounds having the formula (I), which are cyclooxygenase (COX) inhibitors The compounds are selective inhibitors of cyclooxygenase-2-(COX-2), which is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1), which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDS).